VNRX
VolitionRx Limited
Medical - Diagnostics & Research
Market Cap$13M
5Y Perf.-96.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
VNRX vs EXAS
Revenue, margins, valuation, and 5-year total return — side by side.
EXAS
Exact Sciences Corporation
Medical - Diagnostics & Research
Market Cap$20.02B
5Y Perf.+20.4%
VNRX vs EXAS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | VNRX | EXAS |
|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Diagnostics & Research |
| Market Cap | $13M | $20.02B |
| Revenue (TTM) | $2M | $3.25B |
| Net Income (TTM) | $-23M | $-208M |
| Gross Margin | 100.0% | 69.7% |
| Operating Margin | -12.5% | -6.4% |
| Forward P/E | — | 582.8x |
| Total Debt | $11M | $2.52B |
| Cash & Equiv. | $1M | $956M |
VNRX vs EXAS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
VNRX
EXAS
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| VolitionRx Limited (VNRX) | 100 | 3.9 | -96.1% |
| Exact Sciences Corp… (EXAS) | 100 | 120.4 | +20.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VNRX vs EXAS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: EXAS leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. VolitionRx Limited is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
VNRX
VolitionRx Limited
The Growth Play
VNRX is the clearest fit if your priority is growth exposure.
- Rev growth 40.0%, EPS growth 29.0%, 3Y rev CAGR 78.0%
- 40.0% revenue growth vs EXAS's 17.7%
Best for: growth exposure
EXAS
Exact Sciences Corporation
The Income Pick
EXAS carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.12
- 16.7% 10Y total return vs VNRX's -96.2%
- Lower volatility, beta 0.12, current ratio 2.43x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | VNRX | 40.0% revenue growth vs EXAS's 17.7% |
| Quality / Margins | EXAS | -6.4% margin vs VNRX's -13.5% |
| Stability / Safety | EXAS | Beta 0.12 vs VNRX's 0.17 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | EXAS | +96.9% vs VNRX's -76.7% |
| Efficiency (ROA) | EXAS | -3.5% ROA vs VNRX's -305.6% |
VNRX vs EXAS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
VNRX vs EXAS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLEXASLAGGINGVNRX
VNRXVolitionRx Limited
0leads
EXASExact Sciences Corpor…
5leads
6 Total Categories
CATEGORYLEADERvs VNRXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
EXAS4/6
Valuation MetricsMultiples, price ratios, and targets
EXAS2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
EXAS3/5
Total Returns1Y, 3Y, 5Y total returns with dividends
EXAS6/6
Risk & VolatilityBeta, volatility, and downside exposure
EXAS2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
EXAS leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
EXAS is the larger business by revenue, generating $3.2B annually — 1879.7x VNRX's $2M. EXAS is the more profitable business, keeping -6.4% of every revenue dollar as net income compared to VNRX's -13.5%. On growth, VNRX holds the edge at +133.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | VNRXVolitionRx Limited | EXASExact Sciences Co… |
|---|---|---|
| RevenueTrailing 12 months | $2M | $3.2B |
| EBITDAEarnings before interest/tax | -$20M | -$41M |
| Net IncomeAfter-tax profit | -$23M | -$208M |
| Free Cash FlowCash after capex | -$20M | $357M |
| Gross MarginGross profit ÷ Revenue | +100.0% | +69.7% |
| Operating MarginEBIT ÷ Revenue | -12.5% | -6.4% |
| Net MarginNet income ÷ Revenue | -13.5% | -6.4% |
| FCF MarginFCF ÷ Revenue | -11.4% | +11.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +133.2% | +23.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +20.5% | +90.4% |
EXAS leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
EXAS leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | VNRXVolitionRx Limited | EXASExact Sciences Co… |
|---|---|---|
| Market CapShares × price | $13M | $20.0B |
| Enterprise ValueMkt cap + debt − cash | $23M | $21.6B |
| Trailing P/EPrice ÷ TTM EPS | -0.55x | -95.37x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 582.83x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 7.49x | 6.16x |
| Price / BookPrice ÷ Book value/share | — | 8.24x |
| Price / FCFMarket cap ÷ FCF | — | 56.10x |
EXAS leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
EXAS leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), EXAS scores 7/9 vs VNRX's 2/9, reflecting strong financial health.
| Metric | VNRXVolitionRx Limited | EXASExact Sciences Co… |
|---|---|---|
| ROE (TTM)Return on equity | — | -8.7% |
| ROA (TTM)Return on assets | -3.1% | -3.5% |
| ROICReturn on invested capital | — | -3.6% |
| ROCEReturn on capital employed | — | -4.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 7 |
| Debt / EquityFinancial leverage | — | 1.05x |
| Net DebtTotal debt minus cash | $10M | $1.6B |
| Cash & Equiv.Liquid assets | $1M | $956M |
| Total DebtShort + long-term debt | $11M | $2.5B |
| Interest CoverageEBIT ÷ Interest expense | -8.44x | -5.47x |
EXAS leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
EXAS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in EXAS five years ago would be worth $10,039 today (with dividends reinvested), compared to $388 for VNRX. Over the past 12 months, EXAS leads with a +96.9% total return vs VNRX's -76.7%. The 3-year compound annual growth rate (CAGR) favors EXAS at 15.2% vs VNRX's -60.7% — a key indicator of consistent wealth creation.
| Metric | VNRXVolitionRx Limited | EXASExact Sciences Co… |
|---|---|---|
| YTD ReturnYear-to-date | -55.7% | +3.1% |
| 1-Year ReturnPast 12 months | -76.7% | +96.9% |
| 3-Year ReturnCumulative with dividends | -94.0% | +53.0% |
| 5-Year ReturnCumulative with dividends | -96.1% | +0.4% |
| 10-Year ReturnCumulative with dividends | -96.2% | +1669.1% |
| CAGR (3Y)Annualised 3-year return | -60.7% | +15.2% |
EXAS leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
EXAS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
EXAS is the less volatile stock with a 0.12 beta — it tends to amplify market swings less than VNRX's 0.17 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EXAS currently trades 99.9% from its 52-week high vs VNRX's 12.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | VNRXVolitionRx Limited | EXASExact Sciences Co… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.17x | 0.12x |
| 52-Week HighHighest price in past year | $18.80 | $104.98 |
| 52-Week LowLowest price in past year | $0.27 | $38.81 |
| % of 52W HighCurrent price vs 52-week peak | +12.9% | +99.9% |
| RSI (14)Momentum oscillator 0–100 | 31.6 | 76.4 |
| Avg Volume (50D)Average daily shares traded | 714K | 4.2M |
EXAS leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | VNRXVolitionRx Limited | EXASExact Sciences Co… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $103.18 |
| # AnalystsCovering analysts | — | 41 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.1% |
Insufficient data to determine a leader in this category.
Key Takeaway
EXAS leads in 5 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics.
Best OverallExact Sciences Corporation (EXAS)Leads 5 of 6 categories
Loading custom metrics...
VNRX vs EXAS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is VNRX or EXAS a better buy right now?
For growth investors, VolitionRx Limited (VNRX) is the stronger pick with 40.
0% revenue growth year-over-year, versus 17. 7% for Exact Sciences Corporation (EXAS). Analysts rate Exact Sciences Corporation (EXAS) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — VNRX or EXAS?
Over the past 5 years, Exact Sciences Corporation (EXAS) delivered a total return of +0.
4%, compared to -96. 1% for VolitionRx Limited (VNRX). Over 10 years, the gap is even starker: EXAS returned +1669% versus VNRX's -96. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — VNRX or EXAS?
By beta (market sensitivity over 5 years), Exact Sciences Corporation (EXAS) is the lower-risk stock at 0.
12β versus VolitionRx Limited's 0. 17β — meaning VNRX is approximately 45% more volatile than EXAS relative to the S&P 500.
04Which is growing faster — VNRX or EXAS?
By revenue growth (latest reported year), VolitionRx Limited (VNRX) is pulling ahead at 40.
0% versus 17. 7% for Exact Sciences Corporation (EXAS). On earnings-per-share growth, the picture is similar: Exact Sciences Corporation grew EPS 80. 3% year-over-year, compared to 29. 0% for VolitionRx Limited. Over a 3-year CAGR, VNRX leads at 78. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — VNRX or EXAS?
Exact Sciences Corporation (EXAS) is the more profitable company, earning -6.
4% net margin versus -1352. 2% for VolitionRx Limited — meaning it keeps -6. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EXAS leads at -6. 4% versus -1228. 6% for VNRX. At the gross margin level — before operating expenses — VNRX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — VNRX or EXAS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is VNRX or EXAS better for a retirement portfolio?
For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
12), +1669% 10Y return). Both have compounded well over 10 years (EXAS: +1669%, VNRX: -96. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between VNRX and EXAS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(VNRX: 133.2% · EXAS: 23.1%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.